Pharvaris says Lancet publishes RAPIDe-3 data on deucrictibant

Pharvaris said on 8 October 2026 that results from its phase 3 RAPIDe-3 study of deucrictibant immediate-release capsule 20 mg have been published in The Lancet, with the treatment reaching symptom relief in 1.28 hours and complete symptom resolution in 11.95 hours.

The study evaluated oral deucrictibant IR as an on-demand treatment for hereditary angioedema, or HAE, attacks in adolescents and adults. Pharvaris said RAPIDe-3 was global, randomized, double-blind, placebo-controlled and crossover, and that the drug was well tolerated with no safety signals observed.

According to the company, the trial met its primary endpoint and all 11 secondary endpoints with high statistical significance. It said deucrictibant IR achieved End of Progression of attack symptoms, symptom relief and complete symptom resolution faster than placebo, and that most attacks were adequately controlled with a single capsule.

Pharvaris said the results were consistent across subgroups defined by age, geographic location, HAE type, use of long-term prophylaxis, and attack severity and location, including non-severe laryngeal attacks. The company added that the findings were consistent with RAPIDe-1, which it said was published in The Lancet Haematology in April 2026.

The company said a New Drug Application for deucrictibant IR is under review with the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act target action date of 23 April 2027. It also said a Marketing Authorization Application is under review with the European Medicines Agency.

Pharvaris said an open-label extension study, RAPIDe-2, is ongoing, and that an expanded access program is also available to eligible people in the U.S.